US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Septerna, Inc.

37.75

-0.2200-0.58%

Post-market: 37.750.00000.00%19:30 EDT

Volume:338.72K

Turnover:12.84M

Market Cap:1.76B

PE:-69.59

High:38.43

Open:37.37

Low:36.60

Close:37.97

52wk High:51.10

52wk Low:13.67

Shares:46.68M

Float Shares:22.90M

Volume Ratio:1.14

T/O Rate:1.48%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5424

EPS(LYR):-1.1044

ROE:-6.34%

ROA:-7.13%

PB:4.56

PE(LYR):-34.18

Loading ...

Overview Company News Filings

Septerna Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Septerna reports Q1 EPS (19c), consensus (27c)

Septerna Q1 revenue rises sharply helped by Novo Nordisk collaboration

Septerna Q1 EPS $(0.19) Beats $(0.42) Estimate, Sales $26.523M Beat $16.938M Estimate

Benzinga Earnings

Septerna Q1 FY26 net loss narrows to $8.6 million; revenue rises to $26.5 million

Press Release: Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Septerna CEO presents at Bank of America Securities Health Care Conference

Septerna announces annual shareholder meeting

Septerna initiated with a Buy at Stifel

Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial?

Simply Wall St.

Analysts Offer Insights on Technology Companies: Vicor (VICR), Ceragon Networks (CRNT) and Septerna, Inc. (SEPN)

Septerna President, COO Elizabeth Bhatt disposes 4,000 shares for $88,198.44

Septerna Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target

Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy?

Simply Wall St.

Septerna starts Phase 1 trial of SEP-479 oral hypoparathyroidism drug

Septerna Inc - Phase 1 Trial Expected to Enroll up to 150 Participants

THOMSON REUTERS

Septerna Inc - Phase 1 Trial Data Expected in Late 2026 or Early 2027

THOMSON REUTERS

Septerna Is Maintained at Overweight by JP Morgan

Should Septerna’s New ATM and Shelf Offering Strategy Require Action From Septerna (SEPN) Investors?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/SEPN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SEPN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","market":"US","secType":"STK","nameCN":"Septerna, Inc.","latestPrice":37.75,"timestamp":1789070400000,"preClose":37.97,"halted":0,"volume":338723,"hourTrading":{"tag":"盘后","latestPrice":37.75,"preClose":37.75,"latestTime":"19:30 EDT","volume":6532,"amount":246583,"timestamp":1789083007756,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.005794047932578322,"floatShares":22896300,"shares":46676947,"eps":-0.542426,"marketStatus":"Not Yet Opened","change":-0.22,"latestTime":"09-10 16:00:00 EDT","open":37.37,"high":38.43,"low":36.6,"amount":12836406.00781,"amplitude":0.048196,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.542426,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":0,"adr":0,"listingDate":1729828800000,"exchange":"NASDAQ","adjPreClose":37.97,"preHourTrading":{"tag":"盘前","latestPrice":37.21,"preClose":37.97,"latestTime":"09:28 EDT","volume":2,"amount":75.1,"timestamp":1789046899013,"change":-0.76,"changeRate":-0.020016,"amplitude":0.017909},"postHourTrading":{"tag":"盘后","latestPrice":37.75,"preClose":37.75,"latestTime":"19:30 EDT","volume":6532,"amount":246583,"timestamp":1789083007756,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.136897,"impliedVol":1.1295,"impliedVolPercentile":0.9841},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","floatShares":22896300,"roa":"-7.13%","roe":"-6.34%","lyrEps":-1.104402,"volumeRatio":1.136897,"shares":46676947,"dividePrice":0,"high":38.43,"amplitude":0.048196,"preClose":37.97,"low":36.6,"week52Low":13.67,"pbRate":"4.56","psRate":"17.82","week52High":51.1,"institutionHeld":0,"latestPrice":37.75,"eps":-0.542426,"divideRate":0,"volume":338723,"delay":0,"ttmEps":-0.542426,"open":37.37,"prevYearClose":27.88,"prevWeekClose":36.75,"prevMonthClose":38.15,"prevQuarterClose":33.49,"fiveDayClose":37.5,"twentyDayClose":48.19,"sixtyDayClose":36.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SEPN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"SEPN","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"post","actualEps":-0.29},{"market":"US","date":"2026-05-11","symbol":"SEPN","fiscalQuarterEnding":"2026/03","expectedEps":-0.51,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-0.19},{"market":"US","date":"2026-03-09","symbol":"SEPN","fiscalQuarterEnding":"2025/12","expectedEps":-0.23,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773028800000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2025-11-10","symbol":"SEPN","fiscalQuarterEnding":"2025/09","expectedEps":0.19,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.09},{"market":"US","date":"2025-08-11","symbol":"SEPN","fiscalQuarterEnding":"2025/06","expectedEps":-0.05,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.56}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SEPN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SEPN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.7,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7,"analysts":10,"updateTime":1781236800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SEPN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SEPN","date":"2026-09-09","current":-69.594747,"percent":0.03871,"low":-92.81078,"twenty":-42.774229,"median":-19.882638,"eighty":-6.111366,"high":261.261398,"avg":-15.780955,"sd":53.512568,"marketCap":1744317509},"quantilePoints":[{"date":"2024-10-25","current":180.873276,"twenty":180.873276,"median":180.873276,"eighty":180.873276,"marketCap":756050292},{"date":"2024-10-31","current":204.688257,"twenty":197.111676,"median":204.688257,"eighty":209.813,"marketCap":855596913},{"date":"2024-11-08","current":261.261398,"twenty":203.984861,"median":216.997688,"eighty":242.57116,"marketCap":1092072644},{"date":"2024-11-15","current":224.885772,"twenty":207.743006,"median":230.613426,"eighty":256.156752,"marketCap":940022529},{"date":"2024-11-22","current":-56.371082,"twenty":203.984861,"median":228.503238,"eighty":245.706296,"marketCap":915240881},{"date":"2024-11-29","current":-69.163916,"twenty":-57.105794,"median":221.92146,"eighty":240.581553,"marketCap":1122945345},{"date":"2024-12-06","current":-68.890433,"twenty":-66.926823,"median":208.506693,"eighty":237.707678,"marketCap":1118505070},{"date":"2024-12-13","current":-61.725172,"twenty":-67.501138,"median":191.022276,"eighty":236.763117,"marketCap":1002169886},{"date":"2024-12-20","current":-63.995083,"twenty":-66.784612,"median":-58.207863,"eighty":234.592638,"marketCap":1039024162},{"date":"2024-12-27","current":-70.449288,"twenty":-68.420042,"median":-60.166317,"eighty":232.180994,"marketCap":1143814633},{"date":"2025-01-03","current":-58.388676,"twenty":-68.655237,"median":-61.232902,"eighty":229.769351,"marketCap":947998541},{"date":"2025-01-10","current":-57.02126,"twenty":-67.714455,"median":-60.412452,"eighty":226.39305,"marketCap":925797170},{"date":"2025-01-17","current":-46.437457,"twenty":-67.358927,"median":-58.853597,"eighty":224.885772,"marketCap":753958559},{"date":"2025-01-24","current":-50.266223,"twenty":-66.593173,"median":-57.614562,"eighty":220.142874,"marketCap":816122397},{"date":"2025-01-31","current":-48.433885,"twenty":-66.401735,"median":-55.982023,"eighty":215.822012,"marketCap":786372560},{"date":"2025-02-07","current":-38.861971,"twenty":-65.110894,"median":-50.840537,"eighty":209.813,"marketCap":630962963},{"date":"2025-02-14","current":-31.587316,"twenty":-64.153703,"median":-49.199638,"eighty":205.451944,"marketCap":512851670},{"date":"2025-02-21","current":-16.108164,"twenty":-63.748948,"median":-46.492154,"eighty":202.578068,"marketCap":261532150},{"date":"2025-02-28","current":-15.862029,"twenty":-63.55204,"median":-46.410109,"eighty":188.992476,"marketCap":257535903},{"date":"2025-03-07","current":-17.393535,"twenty":-63.169163,"median":-46.191322,"eighty":63.291545,"marketCap":282401439},{"date":"2025-03-14","current":-17.47558,"twenty":-62.928498,"median":-43.237703,"eighty":-15.145503,"marketCap":283733521},{"date":"2025-03-21","current":-16.81922,"twenty":-62.747999,"median":-39.764466,"eighty":-15.424456,"marketCap":273076863},{"date":"2025-03-28","current":-3.893469,"twenty":-62.08617,"median":-37.439858,"eighty":-15.424456,"marketCap":279543299},{"date":"2025-04-04","current":-3.590162,"twenty":-61.462628,"median":-35.44343,"eighty":-3.701581,"marketCap":257766476},{"date":"2025-04-11","current":-3.194007,"twenty":-61.271189,"median":-31.04035,"eighty":-3.397655,"marketCap":229323279},{"date":"2025-04-17","current":-3.707771,"twenty":-61.249311,"median":-18.610536,"eighty":-3.429843,"marketCap":266210551},{"date":"2025-04-25","current":-3.998698,"twenty":-60.904722,"median":-17.913153,"eighty":-3.49979,"marketCap":287098524},{"date":"2025-05-02","current":-4.419614,"twenty":-60.313998,"median":-17.530277,"eighty":-3.557975,"marketCap":317319421},{"date":"2025-05-09","current":-4.302005,"twenty":-59.827198,"median":-17.393535,"eighty":-3.586448,"marketCap":308875347},{"date":"2025-05-16","current":-5.700187,"twenty":-58.946582,"median":-17.1474,"eighty":-3.607494,"marketCap":450930380},{"date":"2025-05-23","current":-5.339701,"twenty":-58.316351,"median":-16.81922,"eighty":-3.64092,"marketCap":422413044},{"date":"2025-05-30","current":-5.553739,"twenty":-57.970542,"median":-16.682479,"eighty":-3.660728,"marketCap":439345212},{"date":"2025-06-06","current":-5.925491,"twenty":-56.891224,"median":-16.203883,"eighty":-3.697867,"marketCap":468753715},{"date":"2025-06-13","current":-5.863532,"twenty":-56.29327,"median":-16.053467,"eighty":-3.717675,"marketCap":463852298},{"date":"2025-06-20","current":-5.908593,"twenty":-55.982023,"median":-15.862029,"eighty":-3.757291,"marketCap":467416965},{"date":"2025-06-27","current":-6.122632,"twenty":-53.001056,"median":-15.383433,"eighty":-3.77586,"marketCap":484349134},{"date":"2025-07-03","current":-6.404261,"twenty":-51.513306,"median":-10.750269,"eighty":-3.795668,"marketCap":506628303},{"date":"2025-07-11","current":-6.578872,"twenty":-50.660039,"median":-6.404261,"eighty":-3.874899,"marketCap":520441387},{"date":"2025-07-18","current":-7.108336,"twenty":-50.32092,"median":-6.590137,"eighty":-3.893469,"marketCap":562326225},{"date":"2025-07-25","current":-7.6378,"twenty":-49.412955,"median":-6.753482,"eighty":-3.9727,"marketCap":604211063},{"date":"2025-08-01","current":-6.990051,"twenty":-48.587036,"median":-6.961888,"eighty":-3.99746,"marketCap":552968974},{"date":"2025-08-08","current":-6.590137,"twenty":-46.8805,"median":-6.764747,"eighty":-3.998698,"marketCap":521332554},{"date":"2025-08-15","current":-5.951139,"twenty":-46.492154,"median":-6.643647,"eighty":-4.11805,"marketCap":520754376},{"date":"2025-08-22","current":-5.961329,"twenty":-46.448396,"median":-6.601402,"eighty":-4.167728,"marketCap":521646079},{"date":"2025-08-29","current":-6.256848,"twenty":-46.3937,"median":-6.581688,"eighty":-4.266238,"marketCap":547505457},{"date":"2025-09-05","current":-7.194356,"twenty":-46.300716,"median":-6.581688,"eighty":-4.297053,"marketCap":629542106},{"date":"2025-09-12","current":-7.34721,"twenty":-46.213201,"median":-6.601402,"eighty":-4.305719,"marketCap":642917646},{"date":"2025-09-19","current":-8.121674,"twenty":-44.993466,"median":-6.643647,"eighty":-4.319893,"marketCap":710687051},{"date":"2025-09-26","current":-8.534381,"twenty":-43.94876,"median":-6.764747,"eighty":-4.33085,"marketCap":746801011},{"date":"2025-10-03","current":-10.266733,"twenty":-43.12831,"median":-6.961888,"eighty":-4.351524,"marketCap":898390470},{"date":"2025-10-10","current":-11.790184,"twenty":-42.592283,"median":-7.068908,"eighty":-4.39733,"marketCap":1031700023},{"date":"2025-10-17","current":-11.497212,"twenty":-40.869338,"median":-7.146788,"eighty":-4.427042,"marketCap":1006063571},{"date":"2025-10-24","current":-11.102338,"twenty":-39.518331,"median":-7.194356,"eighty":-4.55084,"marketCap":971510091},{"date":"2025-10-31","current":-10.949483,"twenty":-39.058879,"median":-7.339567,"eighty":-4.913908,"marketCap":958134551},{"date":"2025-11-07","current":-9.578887,"twenty":-37.155435,"median":-7.357401,"eighty":-5.147066,"marketCap":838200538},{"date":"2025-11-14","current":-14.648361,"twenty":-35.886473,"median":-7.487327,"eighty":-5.196633,"marketCap":861455454},{"date":"2025-11-21","current":-18.097273,"twenty":-35.585642,"median":-7.6378,"eighty":-5.267603,"marketCap":1064282543},{"date":"2025-11-28","current":-22.094357,"twenty":-33.900984,"median":-7.78988,"eighty":-5.319423,"marketCap":1299347051},{"date":"2025-12-05","current":-19.916898,"twenty":-31.401348,"median":-8.060532,"eighty":-5.378003,"marketCap":1171292862},{"date":"2025-12-12","current":-19.954966,"twenty":-31.056759,"median":-8.182815,"eighty":-5.451226,"marketCap":1173531572},{"date":"2025-12-19","current":-20.96756,"twenty":-27.412726,"median":-8.753473,"eighty":-5.501919,"marketCap":1233081247},{"date":"2025-12-26","current":-22.436964,"twenty":-22.503963,"median":-9.413294,"eighty":-5.544727,"marketCap":1319495438},{"date":"2026-01-02","current":-21.226419,"twenty":-22.436964,"median":-9.632386,"eighty":-5.553739,"marketCap":1248304472},{"date":"2026-01-09","current":-19.597131,"twenty":-22.436964,"median":-9.915167,"eighty":-5.569002,"marketCap":1152487702},{"date":"2026-01-16","current":-20.845744,"twenty":-22.436964,"median":-10.381374,"eighty":-5.593168,"marketCap":1225917376},{"date":"2026-01-23","current":-20.305186,"twenty":-22.162878,"median":-10.567347,"eighty":-5.611192,"marketCap":1194127700},{"date":"2026-01-30","current":-18.120114,"twenty":-22.094357,"median":-10.857771,"eighty":-5.615698,"marketCap":1065625769},{"date":"2026-02-06","current":-18.607377,"twenty":-21.850725,"median":-11.071767,"eighty":-5.615698,"marketCap":1094281252},{"date":"2026-02-13","current":-19.612358,"twenty":-21.722819,"median":-11.209336,"eighty":-5.64356,"marketCap":1153383185},{"date":"2026-02-20","current":-20.61734,"twenty":-21.739568,"median":-11.372381,"eighty":-5.676942,"marketCap":1212485119},{"date":"2026-02-27","current":-23.053657,"twenty":-22.094357,"median":-11.478105,"eighty":-5.697934,"marketCap":1355762533},{"date":"2026-03-06","current":-20.914266,"twenty":-22.094357,"median":-11.754518,"eighty":-5.704017,"marketCap":1229947054},{"date":"2026-03-13","current":-24.295691,"twenty":-22.288862,"median":-11.879349,"eighty":-5.719638,"marketCap":1187549060},{"date":"2026-03-20","current":-22.30665,"twenty":-22.436964,"median":-13.780423,"eighty":-5.741868,"marketCap":1090326760},{"date":"2026-03-27","current":-22.729264,"twenty":-22.436964,"median":-14.644554,"eighty":-5.761019,"marketCap":1110983692},{"date":"2026-04-02","current":-22.389336,"twenty":-22.436964,"median":-14.872318,"eighty":-5.77679,"marketCap":1094368334},{"date":"2026-04-10","current":-22.811949,"twenty":-22.645844,"median":-15.588546,"eighty":-5.790308,"marketCap":1115025266},{"date":"2026-04-17","current":-22.958945,"twenty":-22.751313,"median":-15.862029,"eighty":-5.81451,"marketCap":1122210286},{"date":"2026-04-24","current":-22.940571,"twenty":-22.897489,"median":-16.108164,"eighty":-5.8559,"marketCap":1121312158},{"date":"2026-05-01","current":-21.828913,"twenty":-22.897489,"median":-16.346578,"eighty":-5.87705,"marketCap":1066975446},{"date":"2026-05-08","current":-22.031033,"twenty":-22.828174,"median":-16.573085,"eighty":-5.90051,"marketCap":1076854848},{"date":"2026-05-15","current":-35.420064,"twenty":-23.014069,"median":-16.805546,"eighty":-5.906606,"marketCap":1276539094},{"date":"2026-05-22","current":-34.91978,"twenty":-23.096754,"median":-17.065355,"eighty":-5.913099,"marketCap":1258508881},{"date":"2026-05-29","current":-38.834498,"twenty":-23.422893,"median":-17.338839,"eighty":-5.920985,"marketCap":1399595299},{"date":"2026-06-05","current":-39.234724,"twenty":-23.969543,"median":-17.448232,"eighty":-5.926617,"marketCap":1414019470},{"date":"2026-06-12","current":-42.561609,"twenty":-25.529539,"median":-17.587169,"eighty":-5.93225,"marketCap":1533920387},{"date":"2026-06-18","current":-44.775363,"twenty":-30.958305,"median":-17.712792,"eighty":-5.936756,"marketCap":1613704081},{"date":"2026-06-26","current":-43.19947,"twenty":-32.893633,"median":-17.963339,"eighty":-5.951139,"marketCap":1556908909},{"date":"2026-07-02","current":-43.28702,"twenty":-34.942293,"median":-18.108694,"eighty":-5.953151,"marketCap":1560064197},{"date":"2026-07-10","current":-47.326808,"twenty":-35.535865,"median":-18.432772,"eighty":-5.955718,"marketCap":1705658168},{"date":"2026-07-17","current":-39.472359,"twenty":-37.456217,"median":-18.865336,"eighty":-5.96031,"marketCap":1422583821},{"date":"2026-07-24","current":-41.861212,"twenty":-38.129098,"median":-19.056573,"eighty":-5.968707,"marketCap":1508678089},{"date":"2026-07-31","current":-43.999924,"twenty":-38.804481,"median":-19.345886,"eighty":-5.971132,"marketCap":1585757250},{"date":"2026-08-07","current":-49.440506,"twenty":-39.282531,"median":-19.37634,"eighty":-6.008114,"marketCap":1781835819},{"date":"2026-08-14","current":-86.93668,"twenty":-40.880657,"median":-19.444862,"eighty":-6.039269,"marketCap":2106997387},{"date":"2026-08-21","current":-78.558866,"twenty":-41.886226,"median":-19.559064,"eighty":-6.073792,"marketCap":1903952668},{"date":"2026-08-28","current":-77.942567,"twenty":-42.501575,"median":-19.616165,"eighty":-6.102974,"marketCap":1889016045},{"date":"2026-09-04","current":-70.874387,"twenty":-42.643277,"median":-19.810309,"eighty":-6.110455,"marketCap":1717711649},{"date":"2026-09-09","current":-71.97217,"twenty":-42.774229,"median":-19.882638,"eighty":-6.111366,"marketCap":1744317509}],"updateTime":1789106935869},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SEPN\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635978936","title":"Septerna Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2635978936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635978936?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:17","pubTimestamp":1778671020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SEPN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 07:17 ET (11:17 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634253251","title":"Septerna reports Q1 EPS (19c), consensus (27c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634253251","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634253251?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:33","pubTimestamp":1778535222,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $26.52M, consensus $15.09M. “In the first quarter, we continued to make meaningful progress across our pipeline, highlighted by ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/septerna-reports-q1-eps-19c-consensus-27c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/septerna-reports-q1-eps-19c-consensus-27c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634258399","title":"Septerna Q1 revenue rises sharply helped by Novo Nordisk collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2634258399","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634258399?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:52","pubTimestamp":1778532722,"startTime":"0","endTime":"0","summary":"Septerna Q1 revenue rises sharply helped by Novo Nordisk collaborationOverviewUS biotechnology firm's Q1 revenue rose sharply, beating analyst expectationsCompany posted a narrower net loss compared t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL1N41O137:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634872237","title":"Septerna Q1 EPS $(0.19) Beats $(0.42) Estimate, Sales $26.523M Beat $16.938M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634872237","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634872237?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:10","pubTimestamp":1778530228,"startTime":"0","endTime":"0","summary":"Septerna Q1 EPS $(0.19) Beats $(0.42) Estimate, Sales $26.523M Beat $16.938M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/SEPN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Septerna Q1 EPS $(0.19) Beats $(0.42) Estimate, Sales $26.523M Beat $16.938M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232102","title":"Septerna Q1 FY26 net loss narrows to $8.6 million; revenue rises to $26.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232102","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232102?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:03","pubTimestamp":1778529807,"startTime":"0","endTime":"0","summary":"Septerna posted a net loss of $8.6 million, narrowing from a $21.5 million loss a year earlier.Revenue climbed to $26.5 million from $219,000, driven by the Novo Nordisk collaboration.R&D expenses rose to $29.5 million from $19.3 million, while G&A costs increased to $10.3 million from $6.9 million.Cash, cash equivalents, and marketable securities totaled $522.1 million, with runway expected to fund operations at least into 2029.Pipeline updates included positive Phase 1 data for SEP-631 supporting Phase 2 development, with a Phase 2b trial in chronic spontaneous urticaria targeted for the second half of 2026, while a Phase 1 study of SEP-479 was initiated with data expected in late 2026 or early 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLbVkN0f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SG9999014021.USD","BK4112","SEPN","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4588","IE00BN0W2T93.GBP","NDAQ","LU2210150020.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","BK4585","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634547232","title":"Press Release: Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634547232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634547232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":"Compelling Phase 1 Data for SEP-631  in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria  in Second Half of 2026. Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism. Cash Position of $522.1 Million Expected to Support Operating Plans at Least into 2029. \"In the first quarter, we continued to make meaningful progress across our pipeline, highlighted by positive Phase 1 clinical results for SEP-631 and the initiation of our Phase 1 clinical trial for SEP-479,\" said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna. \"These advances further validate our Native Complex Platform and its ability to efficiently generate differentiated oral small molecules against historically challenging GPCR targets. As our clinical programs continue to advance, we believe Septerna is increasingly well positioned to unlock the broad therapeutic potential of GPCR-targeted medicines for pa","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","LU2065732104.USD","BK4007","PRGS","SEPN","GPCR","BK4022","BK4599","R","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633910345","title":"Septerna CEO presents at Bank of America Securities Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910345","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910345?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:01","pubTimestamp":1777982504,"startTime":"0","endTime":"0","summary":"Septerna CEO Jeffrey Finer will present at Bank of America Securities Health Care Conference on May 12, 2026, at 5:00 p.m. PT in Las Vegas.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL7ZGp7P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","NDAQ","SEPN","LU2095319765.USD","BK4112","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","SG9999014013.SGD","BK4585","BK4007","IE00BKPKM429.USD","LU0314104364.USD","BK4588","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632566138","title":"Septerna announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632566138","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632566138?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:43","pubTimestamp":1777581782,"startTime":"0","endTime":"0","summary":"Septerna scheduled 2026 annual stockholder meeting for June 26, 2026 in virtual format.Vote set for election of two Class II directors to serve until 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Septerna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL5B9SwS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632369661","title":"Septerna initiated with a Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2632369661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632369661?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:39","pubTimestamp":1777581584,"startTime":"0","endTime":"0","summary":"Stifel analyst Alex Thompson initiated coverage of Septerna (SEPN) with a Buy rating and $43 price target The firm is bullish on Septerna’s G prote...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/septerna-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/septerna-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4007","BK4127","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629054139","title":"Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629054139","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629054139?lang=en_us&edition=fundamental","pubTime":"2026-04-22 01:09","pubTimestamp":1776791388,"startTime":"0","endTime":"0","summary":"Septerna, Inc. recently began dosing healthy volunteers in a randomized, placebo-controlled Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, using single-ascending and multiple-ascending dose designs to assess safety, tolerability, pharmacokinetics and pharmacodynamics.\nThis first-in-human study, which could enroll up to 150 participants and tracks biomarkers such as endogenous PTH and serum calcium, marks a key progression of Septerna’s GPCR-targeted pipeline into...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/is-septerna-sepn-quietly-redefining-its-gpcr-strategy-with-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/is-septerna-sepn-quietly-redefining-its-gpcr-strategy-with-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4599","BK4007","SEPN","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628740113","title":"Analysts Offer Insights on Technology Companies: Vicor (VICR), Ceragon Networks (CRNT) and Septerna, Inc. (SEPN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628740113","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628740113?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:01","pubTimestamp":1776686479,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Vicor (VICR), Ceragon Networks (CRNT) and Septerna, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-technology-companies-vicor-vicr-ceragon-networks-crnt-and-septerna-inc-sepn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-technology-companies-vicor-vicr-ceragon-networks-crnt-and-septerna-inc-sepn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4096","SEPN","VICR","BK4020","TECS","BK4007","ARTY","CRNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628878091","title":"Septerna President, COO Elizabeth Bhatt disposes 4,000 shares for $88,198.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2628878091","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628878091?lang=en_us&edition=fundamental","pubTime":"2026-04-18 07:01","pubTimestamp":1776466885,"startTime":"0","endTime":"0","summary":"Septerna President and COO Elizabeth Bhatt sold 4,000 shares of common stock on April 15, 2026.Sale prices ranged from USD 23.76 to USD 25.86.Bhatt also exercised stock options for 4,000 shares at USD 6.81.Directly held common shares stood at 174,209 following reported transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Septerna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL8SstR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Septerna President, COO Elizabeth Bhatt disposes 4,000 shares for $88,198.44","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627279448","title":"Septerna Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2627279448","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627279448?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:23","pubTimestamp":1776165780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SEPN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 07:23 ET (11:23 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627417425","title":"Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2627417425","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627417425?lang=en_us&edition=fundamental","pubTime":"2026-04-14 18:35","pubTimestamp":1776162925,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Septerna, Inc. today and set a price target of $40.00. Ram Selvaraju has given his...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/septerna-advancing-gpcr-pipeline-and-strategic-partnerships-support-buy-rating-and-40-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/septerna-advancing-gpcr-pipeline-and-strategic-partnerships-support-buy-rating-and-40-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SEPN","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627545758","title":"Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2627545758","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627545758?lang=en_us&edition=fundamental","pubTime":"2026-04-13 23:20","pubTimestamp":1776093656,"startTime":"0","endTime":"0","summary":"Septerna, Inc. recently began dosing healthy adult volunteers in a Phase 1 single- and multiple-ascending dose clinical trial of SEP-479, an oral small molecule PTH1R agonist being developed for hypoparathyroidism.\nThis marks a key progression of Septerna’s GPCR-targeted pipeline into human testing, with initial safety, PK and PD data expected in late 2026 or early 2027.\nNext, we’ll examine how initiating human dosing for SEP-479 and its focus on hypoparathyroidism could shape Septerna’s...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/is-septerna-sepn-using-its-first-pth1r-trial-to-redefine-its","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/is-septerna-sepn-using-its-first-pth1r-trial-to-redefine-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4599","SEPN","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627307394","title":"Septerna starts Phase 1 trial of SEP-479 oral hypoparathyroidism drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2627307394","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627307394?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:04","pubTimestamp":1776081891,"startTime":"0","endTime":"0","summary":"Results have not been presented; Phase 1 data are expected in late 2026 or early 2027.Study will assess whether SEP-479 can be taken safely and support calcium control with once-daily dosing.Trial is designed to enroll up to 150 healthy adults across single-ascending dose and multiple-ascending dose cohorts.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL7nMxQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","IE00BGHQF748.EUR","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014021.USD","BK4112","NDAQ","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4007","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627300634","title":"Septerna Inc - Phase 1 Trial Expected to Enroll up to 150 Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2627300634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627300634?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:00","pubTimestamp":1776081603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUA8DDZNC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627300554","title":"Septerna Inc - Phase 1 Trial Data Expected in Late 2026 or Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2627300554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627300554?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:00","pubTimestamp":1776081603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUA8DDZNC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622097613","title":"Septerna Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622097613","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622097613?lang=en_us&edition=fundamental","pubTime":"2026-03-25 02:22","pubTimestamp":1774376520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SEPN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 14:22 ET (18:22 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621970257","title":"Should Septerna’s New ATM and Shelf Offering Strategy Require Action From Septerna (SEPN) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621970257","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621970257?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:07","pubTimestamp":1774274841,"startTime":"0","endTime":"0","summary":"Earlier in March 2026, Septerna, Inc. reported full-year 2025 results showing sales of US$45.95 million and a narrower net loss of US$48.88 million, followed by a filing for a US$150 million at-the-market follow-on equity offering.\nOn the same date, the company also registered an omnibus shelf covering common and preferred stock, debt securities, warrants and units, giving it broad flexibility to raise capital across multiple instruments over time.\nNext, we’ll examine how Septerna’s new...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/should-septernas-new-atm-and-shelf-offering-strategy-require","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/should-septernas-new-atm-and-shelf-offering-strategy-require","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4211","SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":81,"code":"91000000","status":"200"}]}}